NCT05728775

REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry

REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry (REPOSE-2): A Multicenter Randomized Controlled Trial

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 7,188 (estimated)
• Sponsor: Nanfang Hospital, Southern Medical University · Academic / Other
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

The goal of this randomized controlled trial is to compare total intravenous anesthesia with remimazolam vs total intravenous anesthesia with propofol in moderate-to-high risk patients undergoing major elective noncardiac surgery under general anesthesia. The primary hypothesis is that total intravenous anesthesia with remimazolam can increase days alive and out of hospital at postoperative day 30 compared with total intravenous anesthesia with propofol.

Conditions

• Anesthesia
• Surgery-Complications

Interventions

Type	Name	Description
DRUG	Remimazolam	Remimazolam is administered intravenously for induction and maintenance of general anesthesia.
DRUG	Propofol	Propofol is administered intravenously for induction and maintenance of general anesthesia.

Timeline

• Start date: 2023-04-03
• Primary completion: 2027-12-31
• Completion: 2027-12-31
• First posted: 2023-02-15
• Last updated: 2025-08-26

Locations

44 sites across 1 country: China